Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024

Rhea-AI Summary

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology company developing universally implantable, bioengineered human tissue, will release its Q2 2024 financial results on August 13, 2024. The company will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs. Investors can join via phone (U.S.: 1-877-704-4453, International: 1-201-389-0920, Conference ID: 13747913) or webcast. A replay will be available on the company's investor website for at least 30 days after the event.

News Market Reaction

-16.37%

1 alert

-16.37% News Effect

On the day this news was published, HUMA declined 16.37%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024. Management will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs.

Title:	Humacyte Second Quarter 2024 Financial Results and Corporate Update
Date:	August 13, 2024
Time:	8:30 AM Eastern Time
Conference Call Details:	1-877-704-4453 (U.S. Investors Dial) 1-201-389-0920 (International Investors Dial) 13747913 (Conference ID)
Call me™ Feature:	Click Here
Webcast:	Webcast Link - Click Here

The webcast should be accessible 15 minutes prior to the conference call’s start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review with a PDUFA date of August 10, 2024. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

FAQ

When will Humacyte (HUMA) release its Q2 2024 financial results?

Humacyte (HUMA) will release its Q2 2024 financial results on Tuesday, August 13, 2024.

What time is Humacyte's (HUMA) Q2 2024 earnings call scheduled for?

Humacyte's (HUMA) Q2 2024 earnings call is scheduled for 8:30 a.m. ET on August 13, 2024.

How can investors access Humacyte's (HUMA) Q2 2024 earnings call?

Investors can access Humacyte's (HUMA) Q2 2024 earnings call via phone (U.S.: 1-877-704-4453, International: 1-201-389-0920, Conference ID: 13747913) or through a webcast available on the company's investor website.

What will be discussed during Humacyte's (HUMA) Q2 2024 earnings call?

Humacyte's (HUMA) Q2 2024 earnings call will discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs, in addition to the financial results for the quarter ended June 30, 2024.